Halia Therapeutics Strengthens Leadership with Executive Chairman Appointment and New Directors

Halia Therapeutics Strengthens Leadership with New Appointments

In a significant move to enhance its leadership structure, Halia Therapeutics, a trailblazer in the development of inflammation therapies, has announced the appointment of Gary Sabin as Executive Chairman. The announcement comes alongside the addition of three independent directors to its Board of Directors: Preston Campbell, MD, David Checketts, and Mary Beckerle, PhD. These changes are poised to further propel Halia’s mission of innovating new therapies anchored in protective human genetics.

Strategic Leadership Transition

Gary Sabin, who joined the Halia Board in January 2025, has been an integral part of the company's strategic vision. His extensive experience in capital markets and governance has already made a marked impact on Halia’s operations. His prior positions include key leadership roles at Excel Realty Trust and the Cystic Fibrosis Foundation, where his contributions were pivotal in facilitating FDA approvals for various therapies.

As Halia moves forward, Sabin emphasizes, "Halia's platform uniquely integrates a genetically validated mechanism with clinical evidence that suggests substantial potential." His promotion to Executive Chairman is indicative of the increased responsibilities he will undertake in strengthening the company's governance and strategic initiatives.

The New Board Members

Preston W. Campbell III, MD

Former President and CEO of the Cystic Fibrosis Foundation, Dr. Campbell brings a wealth of clinical development and translational medicine expertise. His role in overseeing major studies in cystic fibrosis positions him as an asset to Halia’s mission of developing genetically informed therapies.

David W. Checketts

A veteran in both media and private equity, Checketts has a rich background in brand building and organizational governance. Having made his mark in the sports and entertainment sector, his insights will be crucial as Halia transitions towards a growth phase.

Mary C. Beckerle, PhD

Recognized as a leader in cancer biology, Dr. Beckerle’s extensive research on cell adhesion and migration will enhance Halia's scientific capabilities. Her previous role at Huntsman Cancer Institute, combined with her board positions at Johnson & Johnson and Exelixis, solidifies her standing as a vital contributor to Halia’s advancement strategies.

Advancements in Research and Development

Halia is currently making strides with its therapeutic pipeline, specifically with HT-6184, which is moving towards pivotal development in lower-risk myelodysplastic syndromes. This advancement follows the recent completion of Phase 2 trials, showcasing promising results that underpin the company's focus on inflammation-driven diseases.

In streamlining its growth and expansion efforts, Halia has also appointed Dr. Han Myint, a seasoned medical professional, as Chief Medical Officer. This appointment further consolidates the leadership team necessary for steering Halia through its upcoming phases of development in the biopharmaceutical landscape.

Commitment to Growth and Innovation

David Bearss, Halia’s Chief Executive Officer, expressed optimistic sentiments regarding the recent appointments. He stated, "We are pleased to formalize Gary's leadership as Executive Chairman, and excited to bring Preston, David, and Mary onto our board. Their collective experience will guide our journey as we aim to expand our pipeline and solidify our position in the industry."

Halia Therapeutics, often termed The Genetic Resilience Company™, leverages groundbreaking research to translate human genetics into effective therapies. Their portfolio not only includes HT-6184 but also extends to HT-4253, aimed at Alzheimer's disease in APOE4 carriers, and HT-6105, which targets inflammatory risk mitigation via hsCRP reduction. These initiatives highlight Halia's commitment to addressing critical health issues with innovative solutions.

With a steadfast focus on advancing medical science through genetic insights, Halia Therapeutics looks poised to make a lasting impact in the biopharmaceutical sector as it embarks on this new chapter of leadership and innovation.